Arrowhead has not initiated research coverage on Admedus yet.

About
Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.
Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.
  • 19
    May
    20
    News Release
    Anti-calcification comparison study
  • 15
    May
    20
    Company Presentation
    Annual General Meeting Address
  • 11
    May
    20
    News Release
    Second Patient successfully implanted in SAVR Trial
  • 22
    Apr
    20
    Corporate Update
    Quarterly Report For The Period To 31 March 2020
  • 9
    Apr
    20
    News Release
    Notice of Annual General Meeting/Proxy Form
  • 9
    Apr
    20
    Corporate Update
    2019 Annual Report
  • 6
    Apr
    20
    News Release
    US FDA clearance for ADAPT® tissue
  • 6
    Apr
    20
    News Release
    First patient in SAVR trial discharged from hospital
  • 27
    Mar
    20
    News Release
    First Patient in SAVR Trial Successfully Implanted
  • 23
    Mar
    20
    Corporate Update
    Total number of +securities proposed to be issued for a placement or other type of issue
  • 20
    Mar
    20
    News Release
    Coronavirus Mitigation Strategy
  • 19
    Mar
    20
    News Release
    Notice of Annual General Meeting and Director Nominations
  • 11
    Mar
    20
    News Release
    Admedus Receives Final Approval By FAMHP For First-In-Human Study
  • 28
    Feb
    20
    News Release
    Preliminary Financial Report
  • 28
    Feb
    20
    Corporate Update
    Appendix 4E and Financial Report
  • 26
    Feb
    20
    News Release
    Results of Extraordinary General Meeting
  • 25
    Feb
    20
    Corporate Update
    Admedus Consolidation
  • 3
    Feb
    20
    News Release
    Admedus Announces Finalisation of License and Associated Milestone Payment with 4C Medical
  • 31
    Jan
    20
    Corporate Update
    Quarterly Report for the Period to 31 December 2019
  • 24
    Jan
    20
    News Release
    Notice of Extraordinary General Meeting
  • 22
    Jan
    20
    News Release
    First-in-human SAVR trial begins Q1 2020
  • 9
    Dec
    19
    News Release
    Update to LeMaitre Vascular deal
  • 19
    Nov
    19
    News Release
    Response to ASX Price and Volume Query
  • 31
    Oct
    19
    News Release
    ADAPT Carve Out Financial Statements
  • 31
    Oct
    19
    Corporate Update
    Appendix 4C - quarterly
  • 15
    Oct
    19
    News Release
    CardioCel and VascuCel LeMaitre deal clarification
  • 14
    Oct
    19
    News Release
    CardioCel and VascuCel rights sold to LeMaitre Vascular
  • 30
    Sep
    19
    News Release
    Extension for Voluntary Suspension
  • 4
    Sep
    19
    News Release
    Cardiocel 3D Approved for Sale in Israel
  • 2
    Sep
    19
    News Release
    Extension for Voluntary Suspension
  • 23
    Aug
    19
    Corporate Update
    Appendix 4D and Half Yearly Financial Report
  • 8
    Aug
    19
    News Release
    Notice to terminate distribution agreement
  • 31
    Jul
    19
    Corporate Update
    Appendix 4C - quarterly
  • 14
    May
    19
    Company Presentation
    2019 AGM Presentation
  • 26
    Apr
    19
    Corporate Update
    Appendix 4C - quarterly
  • 21
    Jan
    19
    Corporate Update
    Appendix 4C - quarterly